Breast Cancer

The authors note further research on technological monitoring methods can help health care providers better optimize patient care and improve nonadherence and nonpersistence.

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.

5. Frank Scimeca, PharmD, MBA, BCOP, leads a discussion on sequencing CDK4/6 inhibitors, comparing their side effect profiles, toxicity benefits, and progression-free survival (PFS) advantages. He emphasizes the need for additional biomarkers and clearer guidance from the NCCN to aid in selecting the most appropriate drug for each patient.

Both MetS and obesity status have independent and differential associations with breast cancer, and may serve as separate targets for breast cancer prediction and prevention strategies.

The study data demonstrate that higher adiposity in childhood results in less dense breast tissue forming, reducing the risk of breast cancer.

Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.

Heather Moore, BCOP, CPP, PharmD, discusses patient adherence to CDK4/6 inhibitors in clinical practice, emphasizing the importance of educating patients on drug efficacy and potential toxicities, monitoring for adverse events, and following up with patients to ensure better adherence.

Key opinion leaders discuss the characteristics they consider when selecting among the different CDK4/6 inhibitors for individual patients, emphasizing the importance of evaluating the toxicity profiles of medications to choose the most appropriate therapy, as well as considering sequencing biomarkers and social determinants of health.

An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice.

The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.

The investigators note that additional research is needed to confirm positive overall survival trends in this patient population.

Trastuzumab is indicated for adjuvant breast cancer, metastatic breast cancer, and gastric cancer.

Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.

Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.

A clinical pharmacist details how treatment algorithms differ between early-stage and metastatic breast cancer.

Expert perspectives on differentiating between the three CDK4/6 inhibitors available for the treatment of metastatic breast cancer are discussed, highlighting factors that inform treatment selection.

Danielle Roman, PharmD, BCOP, discusses the efficacy and safety outcomes of CDK4/6 inhibitors in early-stage breast cancer, as well as key considerations for CDK4/6 inhibitors in this indication.

Danielle Roman, PharmD, BCOP, discusses how the role of the oncology pharmacist has changed in recent years in optimizing early-stage breast cancer treatment with targeted therapies.

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.

The decision follows phase 3 trial results that demonstrated improved progression-free survival and confirmed the safety of Dato-DXd in patients with breast cancer.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

Precision oncology represents an evolution in therapeutic practice.

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

pCR rates improve regardless of whether patients received full chemotherapy doses.

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

No established standard of care currently exists after spread to the lymph nodes.

The combination resulted in numerically longer OS compared with an NSAI alone.

The candidate has already demonstrated anti-tumor activity in chemotherapy-naïve patients.